ATOSSA THERAPEUTICS, INC.
Clinical-stage biopharma developing (Z)-endoxifen for breast cancer treatment and prevention.
ATOS | NDAQ
Overview
Corporate Details
- ISIN(s):
- US04962H5063
- LEI:
- Country:
- United States of America
- Address:
- 10202 5TH AVENUE NE, 98125 SEATTLE
- Website:
- https://atossatherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address significant unmet needs in oncology, specifically for breast cancer treatment and prevention. The company's lead program is the development of (Z)-endoxifen, a proprietary and potent selective estrogen receptor modulator (SERM). Atossa is advancing (Z)-endoxifen to target multiple breast cancer indications across the treatment continuum, including metastatic breast cancer, aiming to improve patient outcomes with a potentially more effective and tolerable therapeutic.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ATOSSA THERAPEUTICS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ATOSSA THERAPEUTICS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ATOSSA THERAPEUTICS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
